Medicare de-fangs new drug pricing model

The Trump administration rolled out the final version of a new Medicare payment model aimed at lowering the prices of drugs administered in doctors' offices to match those paid in countries overseas. The model is designed to reduce costs for Medicare and beneficiaries by aligning U.S. drug prices with international benchmarks, a key policy goal of the administration.